Leukemia, lymphoma, and myeloma together account for ‫ف‬ 500,000 deaths per year worldwide ( 1 ) . HLA-matched allogeneic stem cell transplantation (allo-SCT) is a widely applied immunotherapeutic approach for several of these hematological malignancies. The therapeutic eff ect of allo-SCT is largely mediated by alloreactive donor T cells directed at polymorphic peptides presented by HLA molecules on the recipient ' s malignant cells ( 2 ) . These polymorphic peptides, also known as minor histocompatibility antigens (mHags), are frequently derived from cellular proteins encoded by allelic genes on autosomal chromosomes. Although several mHags are expressed ubiquitously, some mHags are exclusively expressed on hematopoietic cells and their malignant counterparts ( 2 -4 ) . Hence, targeting donor T cells toward such hematopoietic mHags is considered an ideal strategy to establish specifi c antitumor eff ects after allo-SCT ( 2, 4 ) . Because CD8 + T cells are traditionally considered as the eff ector cells of antitumor responses, over the past years the major focus was to identify hematopoietic mHags presented to CD8 + CTLs ( 5 -12 ) . Nonetheless, several reports, including ours, indicate that not only CD8 + CTLs but also CD4 + T cells may possess immunotherapeutic potential ( 13 -15 ) . Yet no hematopoietic mHag presented by HLA class II has been identifi ed, partly because the available techniques are not well suited for identifi cation of such antigens.
More importantly, several of the apparently hematopoietic mHags recognized by CD4 + T cells are not derived from genuine hematopoietic antigens. For instance, the recently identifi ed autosomal mHag presented to CD4 + T cells is derived from the broadly expressed phosphatidylinositol 4-kinase type II ␤ gene ( 16 ) .
We previously isolated an HLA-DQA1*05/B1*02 -restricted mHag-specifi c CD4 + T cell (clone 21) from the PBMC of a multiple myeloma patient after HLA-identical allo-SCT. This clone recognized recipient-derived EBV-transformed B cells (EBV-transformed lymphoblastoid cell lines [EBV-LCLs]) but not the nonhematopoietic fi broblasts and stromal cells, suggesting that its target antigen was encoded by a hematopoietic gene (unpublished data). To identify the mHag recognized by clone 21, we developed a nonlaborious but powerful genetic strategy in which a zygosity-genotype correlation analysis was used for fi ne mapping of the genomic locus mHag identifi ed by classical pair-wise two-point linkage analysis. The new gene-mapping method was also genomewide applicable for a broad range of mHags. Further investigation on the identifi ed locus revealed that the antigen recognized by clone 21 was encoded by a single-nucleotide polymorphism (SNP) in the B cell lineage-specifi c CD19 gene, which is a highly important target antigen for immunotherapy of almost all B cell malignancies. The CD19 L -specifi c CD4 + T cells not only mediated antigen-specifi c help for the induction and expansion of CD8 + mHag-specifi c T cells but also displayed antigen-specifi c and HLA-restricted lysis of CD19 L -positive malignant cells, illustrating the potential therapeutic advantages of targeting this CD19 L -derived HLA class II -restricted mHag. 21 To identify the mHag recognized by clone 21, we started with a genetic approach, the pair-wise two-point linkage analysis. In this method, the genomic locus of the mHag is identifi ed Figure 1 . Five-step identifi cation of the SNP encoding for the mHag recognized by clone 21. (A) mHag phenotypes of CEPH families (indicated with Utah database ID numbers) were determined using methods described in the Materials and methods section. CEPH family 1362 is depicted as an example (male, square; female, circle; mHag + , black; mHag Ϫ , white; undetermined, gray). Phenotypes of families 1331, 1408, and 1416 are given in Fig. S1 (available at http://www.jem.org/cgi/content/full/ jem.20080713/DC1). (B) Genome-wide pairwise two-point linkage analysis using the mHag phenotypes from families 1331, 1362, and 1408. Multiple signifi cant lod scores > 3 (at a recombination fraction of = 0.001) were identifi ed on chromosome 16 in the depicted region. (C) Narrowing of the mHag locus using haplotype data from family 1416. As depicted, the mHag + children 1189 and 2387 inherited the dark gray recombinant haplotype from the father, who is also mHag + . Thus the mHag locus was narrowed to the 16.8-cM region, which is defi ned by the shared part of the paternal allele of children 1189 and 2387. (D) Zygosity-genotype correlation analysis for fi ne mapping the mHag locus. The r 2 values in the y axis represent the correlation between the mHag zygosity of 15 CEPH individuals (Table S1 ) with the genotypes for 4146 HapMap SNPs in this region. Each bar represents a single SNP. Two SNPs (rs7184597 and rs3924376) with 100% correlation (r 2 = 1) are indicated. (E) The location of rs7184597 and rs3924376 (both light gray) in the intronic regions of the RABEP2 gene, which is neighbored by the CD19 gene. Also indicated are the nine nonsynonymous or transcription/translating-altering SNPs in these two genes. The mHag phenotypes and zygosities (Pheno./Zyg.) and the SNP genotypes for fi ve informative CEPH individuals, the SC donor, and the SC recipient are depicted ( Ϫ , deletion of the base pair). Only rs2904880 matched exactly with the phenotypes.
RESULTS

Genetic mapping of the mHag recognized by HLA class II -restricted T cell clone
According to HapMap, these two SNPs were located within the same linkage disequilibrium (LD) block, posing the possibility that the SNP encoding for our mHag could also be located in this block.
Identifi cation of the CD19 L -derived mHag
Within the LD block defi ned by rs7184597 and rs3924376, RABEP2 and CD19 were the only genes with hematopoietic-restricted expression. Therefore, we explored whether RABEP2 and CD19 genes contained nonsynonymous or transcription/translation-altering SNPs that were linked with the SNPs rs7184597 and rs3924376. Genotyping of fi ve representative CEPH family members for nine additional SNPs in RABEP2 and CD19 ( Fig. 1 E ) revealed a single SNP, rs2904880, that was fully matching with the LD block defi ned by rs7184597 and rs3924376. The substitution of guanine for cytosine involved in this SNP causes a change of the valine (V) at position 174 into a leucine (L) within the third exon of CD19 ( Fig. 2 A ) . The fact that the SC recipient was positive for both CD19 L -and CD19 V -encoding alleles, whereas the SC-donor lacked the CD19 L -encoding allele ( Fig. 1 E ) , substantiated the idea that the mHag could be derived from the CD19 L allele. Confi rming this possibility, clone 21 showed strong reactivity against donor EBV-LCLs transduced with a CD19 L -encoding vector but not with an empty vector ( Fig.  2 B ) . Furthermore, clone 21 showed a dose-dependent reactivity against a 15-meric CD19 L peptide PEIWEGEPPC L PPRD, but not against the allelic counterpart peptide, demonstrating the crucial importance of leucine at position 174 for the immunogenicity of the CD19 L -derived mHag ( Fig. 2 C ) . Finally, testing the reactivity of clone 21 against the overlapping 15-mer peptides derived from the polymorphic region revealed that only those peptides containing the core sequence WEGEPPCLP were recognized ( Fig. 2 D ) . Analysis of eight other CD4 + mHag-specifi c T cell clones isolated from the same patient revealed the CD19 L specifi city of three additional T cell clones (unpublished data). All CD19 L -specifi c T cell clones used the same TCR V ␤ 16-CDR3 sequence (unpublished data). We could trace this CD19 L -specifi c TCR in the patient ‫ف‬ 3 mo after SCT, concomitant with the occurrence of an acute graft versus host disease (GvHD) grade III and a strong anti-tumor response, resulting in signifi cant reduction of serum M protein levels ( Fig. 2 E ) . The TCR signal disappeared rapidly after starting immunosuppressive treatment but reappeared soon after tapering immunosuppression, indicating the long-term persistence of CD19 L -specifi c T cells. Discontinuation of immunosuppression led to the development of an extensive and steroid-resistant chronic GvHD, despite the disappearance of CD19 L -specifi c TCR signal from periphery ( Fig. 2 E ) .
Genome-wide application of the novel mHag fi nemapping strategy Our novel strategy was highly eff ective to fi ne map the genetic locus of the CD19 L -mHag defi ned on chromosome 16. Because it would be more convenient if our strategy could be by association of thousands of predefi ned genetic markers to mHag phenotypes (mHag + or mHag Ϫ ) in large pedigrees registered in the Centre d ' Etude du Polymorphisme Humain (CEPH) ( 17 ) . The CEPH families are suitable for this approach because not only have their genomes been screened for genetic markers but also EBV-LCLs are available from each individual. Upon transduction with the appropriate HLA molecules, these cell lines are used as APCs for mHagspecifi c T cells to determine the mHag phenotype of the CEPH individuals. Thus, we fi rst tested the reactivity of clone 21 against (HLA-DQA1*05/B1*02 transduced) EBV-LCLs of several CEPH families ( Fig. 1 A and Fig. S1 , available at http://www.jem.org/cgi/content/full/jem.20080713/DC1) and performed the pairwise two-point linkage analysis in which the mHag phenotype data were correlated with predefi ned genetic markers. Analysis of the data from three families (1331, 1362, and 1408; Fig. 1 A and Fig. S1 ) revealed a signifi cant linkage between the mHag phenotypes and a large cluster of markers on chromosome 16, with multiple lod scores > 3 ( = 0.001; Fig. 1 B ) . According to the CEPH database, two children (1189 and 2387) in a fourth family (1416) displayed a crossing over or recombinant haplotype in this region. As depicted in Fig. 1 C , the mHag in this family was inherited together with the indicated paternal allele because the mHag Ϫ child 1197 inherited the other allele from the mHag + father. Thus, because the two children with recombinant haplotypes were mHag + , the mHag gene should be located in the shared part of their paternal allele, between markers D16S3093 and D16S3034. This area was 16.8 cM on the Marshfi eld Map and contained 270 genes according to National Center for Biotechnology Information Map Viewer.
Development of a novel strategy for fi ne mapping of the mHag locus
The identifi ed mHag locus in chromosome 16 contained too many genes to be analyzed with previously reported strategies ( 8, 9, 17 ) . Therefore, we sought an alternative strategy. Over the last decade, millions of SNPs have been genotyped in CEPH individuals by the International HapMap Project (http://www.hapmap.org/) to facilitate the identifi cation of polymorphic genes associated with human diseases ( 18 ) . We hypothesized that direct correlation of mHag phenotypes with the HapMap SNP genotypes might be useful to fi ne map the genetic locus of our mHag. From the previous linkage analyses, we already knew the mHag phenotype of 23 CEPH individuals included in the HapMap databases. For 15 of these individuals, we also could deduce the mHag zygosity (+/+, +/ Ϫ , or Ϫ / Ϫ ) from the inheritance pattern of the mHag in the pedigrees ( Fig. S1 and Table S1 ). Thus, using a specifi c software that can correlate the zygosity information with the SNP genotypes, we correlated the mHag zygosity information of 15 CEPH individuals with the 4146 HapMap SNPs present in the defi ned region. Despite the seemingly too low numbers of CEPH individuals entered in the analysis, we found a 100% correlation between the mHag zygosities and the genotypes of two intronic SNPs (rs7184597 and rs3924376; Fig. 1 D ) . the mHag zygosity of eight additional CEPH individuals from a recent HapMap release (public release 22), which included the genotypes for the CD19 L -encoding SNP. Indeed, by analyzing the data from 23 CEPH individuals we identifi ed the precise mHag locus ( Fig. 3 ) without any other false positive 100% correlations, demonstrating the feasibility of genome-wide application of our strategy.
directly executed on a genome-wide basis, we correlated the mHag zygosity of 15 CEPH individuals with the complete set of HapMap SNPs from all chromosomes (public release 21a). This fi rst attempt revealed, in addition to the correct locus, several other 100% false-positive correlations throughout the genome (unpublished data), suggesting that mHag zygosity data from more individuals was required. Therefore, we extracted 21 . Genomic DNA isolated from patient PBMCs at the indicated days after allo-SCT was used to amplify the TCR of clone 21. V ␤ 16-specifi c PCR was used as positive control. Genomic DNA from clone 21 (cl.21) and third-party PBMCs (irrel.) were used as positive and negative controls, respectively. Also indicated are the severity of acute and chronic GvHD, the serum M protein levels, and the immunosuppressive prednisone treatment during the monitoring period.
ful for mapping of mHags with frequencies between 10 and 85%. The power beyond these limits decreased signifi cantly.
A potential technical problem of genetic analyses is phenotyping errors. Therefore, we also questioned whether our approach still has any power if the datasets would contain ‫ف‬ 10% false-positive phenotypes. Calculations revealed that such errors cause a certain frequency-dependent reduction in the r 2 values (Fig. S2 , available at http://www.jem.org/cgi/content/ full/jem.20080713/DC1). Nonetheless, we evaluated whether these calculated r 2 values could be used as threshold to discriminate true and false correlations by reexecuting the analyses with 149 SNPs after introducing 7 -10% false-positive phenotypes in the datasets. These analyses resulted in the successful mapping of 96/124 (77%) mHags with frequencies of 10 -85% and only 2/10 SNPs with frequencies of 90% ( Fig. 5 B ) ,
The overall power of the novel mHag fi ne-mapping strategy To determine whether our method is able to locate the genomic locus of other mHags, we fi rst selected six known clinically relevant mHags (Table S2 , available at http://www .jem.org/cgi/content/full/jem.20080713/DC1). After deriving the zygosity of 14 CEPH trios (father-mother-child) for these mHags from the HapMap database, we executed a series of correlation analyses by including data from an increasing number of trios. The results for the representative example mHag HMSD are depicted in Fig. 4 . Although the analysis of the data from seven trios revealed several loci with 100% correlations, false-positive correlations were eff ectively reduced by entering data from more trios. Finally, the correct mHag locus was revealed after analyzing the data from 11 trios. Similarly, the genomic locus of the other fi ve mHags could be identifi ed after analysis of, at most, 14 trios ( Table I ). These successfully mapped mHags displayed frequencies between 35 and 70%. As there are not many known mHags beyond these ranges, in further evaluation, we analyzed 149 nonsynonymous nonlinked HapMap SNPs with frequencies between 5 and 95% (Table S3) as if they are encoding for immunogenic mHags. As depicted in Fig. 5 A , we successfully mapped 121/124 mHags with frequencies of 10 -85%, 4/10 mHags with frequencies of 90%, and 1/15 mHags with frequencies of 5 or 95% using 11 -30 trios. These analyses illustrated that our approach was highly power- Table S1 . For eight other individuals that were also phenotyped by clone 21 recognition, the zygosity information was derived from the rs2904880 genotype information in the latest HapMap release (public release 22; unpublished data). tify a wide range of HLA class I -as well as HLA class II -restricted mHags.
What may be the clinical importance of this novel HLA class II -restricted mHag? Like CD20, CD19 is a B cell lineage-specifi c molecule, with constitutive expression in acute and chronic B cell lymphoid leukemias, B cell lymphomas, and in a subset of acute myeloid leukemias. The expression of CD19 is rarely down-regulated in B cell malignancies. Furthermore, CD19 is not expressed in pluripotent stem cells ( 24 ) . For these reasons, CD19 is widely considered to be an ideal target for immunotherapy of several B cell malignancies. Immunotherapy strategies based on CD19 antibodies (immunotoxins and chimeric TCRs) have been developed and have used both CD4 + and CD8 + T cells as eff ector cells ( 25, 26 ) . Numerous investigators have searched for HLA class I CTL epitopes on the CD19 molecule ( 27 ) . Although these approaches may be very benefi cial, we think that in an immunotherapy setting, targeting of CD19 with CD4 + T cells also may provide several additional benefi ts; in our assays, the CD19 L -specifi c CD4 + T cells not only mediated potent helper functions to activate DCs and stimulate CD8 + CTLs but also directly functioned as eff ector cells to lyse HLAmatched CD19 L -positive malignant cells. Thus, immunotherapy with CD19 L -specifi c CD4 + CTLs alone or in combination with CD8 + T cells may permit the exploitation of both helper and eff ector functions whereby more eff ective and durable antitumor responses may be established. Because CD19 is a B cell -specifi c molecule, CD19 L -specifi c therapy may be feasible not only within but also beyond the allo-SCT settings. The CD19 L allele is expressed in 53% of the Caucasian population, and its antigen-presenting molecule HLA-DQA1*05/B1*02 has a frequency of 15.3% in the Caucasian population. Thus, after an HLA-matched SCT, ‫ف‬ 2.3% of the donor-recipient pairs will be CD19 L mismatched and eligible for a treatment with CD19 L -specifi c CD4 + T cells or vaccination with peptide-loaded or gene-transfected DCs. This percentage can increase up to 8.1% (15.3 × 53%) in an HLA-matched unrelated donor SCT setting or when patients are not transplanted. In all settings, adoptive immunotherapy with ex vivo -generated CD19 L -specifi c T cells may be feasible, in particular after generation of CD19 Lspecifi c T cells using the so-called TCR transfer approach ( 15 ) .
indicating that, despite signifi cant power loss at extreme allele frequencies, our approach may still be useful for the genomic mapping of mHags with frequencies between 10 and 85%, even if the datasets contain 10% false-positive phenotypes.
The immunotherapeutic potential of CD19 L -specifi c T cells
Finally, we explored the possible immunotherapeutic advantages of targeting the CD19 L -encoded HLA class II -restricted antigen by testing the helper and eff ector functions of clone 21. In a coculture system, antigen-specifi c activation of clone 21 with the synthetic peptide or with mHag + APCs facilitated antigen-dependent proliferation of a CD8 + T cell clone specifi c for the mHag LRH-1 ( 9 ) ( Fig. 6 A ) . In another assay, clone 21 induced CD19 L peptide-dependent maturation of HLA-DQ -matched DCs and polarized them to produce signifi cant levels of IL-12 ( Fig. 6 B ) , which is considered essential for licensing DCs to induce CTL responses ( 23 ) . Clone 21 also maturated the DCs that were loaded with apoptotic CD19 L -positive EBV-LCLs ( Fig. 6 C ) . In evaluation of its eff ector functions, clone 21 appeared to secrete high levels of granzyme-B and displayed antigen-specifi c cytotoxic activity against recipient-derived but not against donor-derived EBVLCLs ( Fig. 7, A and B ). Furthermore, when tested against malignant cells derived from various B cell chronic lymphoid leukemia (B-CLL) patients, clone 21 produced signifi cant levels of IFN-␥ ( Fig. 7 C ) and displayed signifi cant antigen-specifi c cytotoxic activity only toward HLA-matched and CD19 Lpositive malignant cells ( Fig. 7 D ) . Collectively, these results indicated that upon adoptive transfer, CD19 L -mHag -specifi c CD4 + T cells may not only provide eff ective help to other effector cells but may also directly contribute to an antitumor eff ect by lysing CD19 L -positive tumor cells.
DISCUSSION
In this paper, we describe the fi rst genuine hematopoietic mHag presented by HLA class II (HLA-DQA1*05/B1*02) molecules to CD4 + T cells. This antigen is encoded by a SNP in the B cell lineage-specifi c CD19 gene. To identify the CD19 Lencoded mHag, we developed a powerful genetic strategy, which is nonlaborious and genome-wide applicable to iden- Fig. 4 . Depicted is the minimal number of trios (Number of trios) resulting in only a single genome locus with 100% correlation, together with the number of CEPH individuals for whom zygosity data was available (Useful number of individuals). Also depicted is the number of SNPs with 100% correlation that was found at this genome locus (Locus: number of r 2 = 1 SNPs).
phenotype frequencies of 10 -85%. The basic idea behind our strategy is similar to a recently introduced method, which utilizes genome association scans after performing SNP array analysis on DNA samples pooled from mHag + and mHag Ϫ individuals ( 28 ) . A major advantage of our strategy is that it covers more SNPs. Although the other method can only analyze 65% of the HapMap SNPs after performing 500,000 SNP arrays, we analyze millions of HapMap SNPs covering the whole genome without even performing an SNP array. Furthermore, our strategy is less laborious. In our analyses, the genome-wide
What may be the impact of our mHag identifi cation strategy? Our novel genetic approach involves a correlation analysis between mHag zygosities and HapMap SNP genotypes to locate the genetic locus of the mHag. Our results demonstrate that this approach is genome-wide applicable and able to precisely map the genetic locus of a wide range of mHags with (Table  S3 , available at http://www.jem.org/cgi/content/full/jem.20080713/DC1). From each SNP one of the alleles was designated to encode for a fi ctive mHag. For each 5% mHag frequency interval between 5 and 95%, and 10, 5, or 4 mHags were analyzed. The analyses were executed for a dataset without phenotyping errors (A) or with 7 -10% false-positive phenotypes (B). The false-positive phenotypes were introduced in the corresponding datasets by randomly changing Ϫ / Ϫ typings into +/ Ϫ , avoiding Mendelian segregation errors. The criterion for positive identification is r 2 = 1 at the genomic locus of the analyzed mHag without any r 2 = 1 false-positive hits at other genomic loci (A), or the criterion is r 2 is above the theoretical r 2 (Fig. S2, available or CD40L-expressing fi broblasts were used as negative and positive controls, respectively. DC maturation was assessed as described in Materials and methods.
78% in the HLA-matched sibling setting or beyond 11 -89% in the HLA-matched unrelated donor setting. Because the number of eligible patients will also be limited by HLA restriction, mHag frequencies beyond these limits are of little practical value for clinical application. Thus, our strategy, with suffi cient power to identify mHags with frequencies of 10 -85%, is actually very suitable for the identifi cation of a vast majority of mHags that are of high value for immunotherapy.
A frequent problem in genetic linkage analyses is phenotyping errors. In our approach, we devoted an extreme attention to avoid such errors because our analyses are executed with a very limited set of CEPH individuals. As phenotype errors will result in the reduction of correlation coeffi cient, our standard criterion of r 2 = 1 to discriminate true-positive hits from false-positive ones cannot be applied for datasets containing phenotype errors. Yet our analyses with datasets containing 10% false-positive phenotypes revealed that the reduction in correlation coeffi cient can be calculated (Fig. S2 ) and that these calculated values could be used as threshold values to eliminate false hits without dramatically reducing the power of the analyses. Thus, our approach, with theoretically adjusted threshold values, may still be useful for identifi cation of clinically relevant mHags even when phenotyping errors cannot be excluded. Nonetheless, as the power decreases signifi cantly we still think that the best strategy for success is to use all means to avoid phenotype errors.
Finally, we think that our strategy is universally applicable because there are fi ve ethnic panels with trios genotyped in the Phase III HapMap. Using one of these panels may be suffi cient for analysis of a wide range of mHag-specifi c T cell clones, even if they are obtained from a diff erent population. In fact, using the Caucasoid CEPH panel, we have been able to map the genomic locus of HMSD, ACC-1 Y , and ACC-2, mHags which were originally described in the Japanese population. Nonetheless, not all HapMap panels consist of trios, which are required for deducing the zygosity information. Because this may still be a potential limitation for identifi cation of mHags in some ethnic populations, we are currently evaluating the possibility of using unrelated HapMap individuals in our strategy. In conclusion, the fi rst HLA class II -restricted hematopoietic mHag as well as the powerful mHag identifi cation strategy described here can signifi cantly facilitate the application of mHag-based immunotherapy in a broader clinical setting.
MATERIALS AND METHODS
Cells.
The HLA-DQA1*05/B1*02-restricted CD4 + T cell clone 21 and the HLA-DP4 -restricted CD4 + control clone 3AB11 were previously isolated from a multiple myeloma patient during the development of acute GvHD grade III and a strong GvT response after allo-SCT from his HLAidentical brother ( 29 ) . In brief, after SCT, PBMCs of the recipient were stimulated with irradiated pre-SCT PBMCs for 3 wk and thereafter expanded with EBV-LCLs derived from pre-SCT PBMCs. T cell clones were obtained by limiting dilution. The HLA-B7 -restricted CD8 + T cell clone specifi c for the mHag LRH-1 was described elsewhere ( 9 ) . T cell clones were expanded using a feeder cell -cytokine mixture as previously described ( 15 ) . EBV-LCLs were cultured in RPMI-1640, 10% FBS (Integro), and antibiotics. The Phoenix packaging line ( -NX-A) and the CD40L-expressing fi broblasts were cultured in DMEM (Invitrogen), 10% FBS, and antibiotics.
identifi cation of the precise LD block of six known mHags required the mHag phenotyping of 27 -42 CEPH individuals, whereas the other approach had to phenotype at least 100 individuals to identify the locus of these mHags ( 28 ) . Thus, our method can dramatically reduce the work load and the time required to identify mHags, which are the two most important drawbacks of all current mHag identifi cation strategies. The only apparent limitation of our strategy may be its diffi culty in identifying mHags with allele frequencies beyond 10 -85%. Nonetheless, it should be emphasized that mHags with very low or high phenotype frequencies are of limited immunotherapeutic value. As illustrated in Fig. S3 (available at http:// www.jem.org/cgi/content/full/jem.20080713/DC1), the chance of an mHag mismatch between the recipient and donor is < 10%, if the mHag phenotype frequency is beyond 26 - (Table S4 , available at http://www.jem.org/cgi/content/full/jem.20080713/DC1) and directly sequenced using BigDye Terminator kit (v3.1; Applied Biosystems) in an automated ABI PRISM 3100 sequencer (Applied Biosystems).
Monitoring of the CD19 L -specifi c TCR. The TCR-␤ chain of clone 21 was amplifi ed from genomic DNA isolated from PBMCs collected periodically after allo-SCT using a TCR-specifi c primer set (Table S4 ). The specifi city of the PCR was controlled using genomic DNA of clone 21 (positive control) and of several irrelevant PBMCs (negative control). FACS-based cytotoxicity assays. The capacity of clone 21 to lyse various mHag + or mHag Ϫ targets (EBV-LCLs or B-CLL cells) was measured in FACS-based 48-h cytotoxicity assays as previously described ( 15 ) . The SEM of duplicate cultures never exceeded 15%.
Statistical analyses.
Where indicated, diff erences between groups were analyzed in two tailed Student ' s t tests with Prism software (GraphPad Software, Inc.). P-values < 0.05 were considered signifi cant.
Online supplemental material. Fig. S1 shows the mHag phenotypes for the individuals of CEPH families 1408, 1416, and 1331. Fig. S2 shows the reduction in correlation coeffi cient in datasets containing 10% false-positive phenotypes. Fig. S3 shows the chance of mHag mismatch between recipient/donor pairs (sibling or unrelated). Table S1 shows detailed phenotypes and zygosities of 15 CEPH individuals and Table S2 shows the input phenotype/zygosity data for retrospective genome-wide analysis. Table S3 shows the 149 SNPs used in the power analyses. CD19-derived peptides. Commercially synthesized and purifi ed (Pepscan) 15-mer peptides were dissolved in DMSO to 100 mM and diluted in PBS to 6 mM to use in functional assays.
Retroviral vectors.
The LZRS-based retroviral vectors containing HLA-DQA1*0501-IRES-GFP or HLA-DQB1*0201-IRES-⌬ NGF-R were provided by F. Koning (Leiden University Medical Center, Leiden, Netherlands). The pMX-CD19 174L -IRES-GFP vector was generated by cloning the CD19 L gene derived from an expression vector (OriGene Technologies). Generation of retroviral supernatants and retroviral transduction of EBVLCLs were described elsewhere ( 15 ) .
mHag phenotyping of CEPH families. To determine the mHag phenotype (mHag + or mHag Ϫ ) of the CEPH individuals, their HLA-DQA1*05/ B1*02 -positive (naturally positive or positive after retroviral transduction) EBV-LCLs were used as APCs for the mHag-specifi c clone 21 at a 1:1 ratio, in a fi nal volume of 200 μ l in U-bottomed 96-well plates. After 18 h of incubation, supernatants were collected and tested for the presence of IFN-␥ using standard ELISA kits. EBV-LCLs were judged mHag + if the mean OD value at 450 nm of triplicate cultures was > 0.250, about four times the background OD value. For < 10% of the CEPH individuals, the OD value was between 0.1 and 0.25. In these cases, assays were repeated at least four times to exactly determine the mHag phenotype of the CEPH individual. Individuals remaining doubtful after fi ve attempts were excluded from the analyses.
ELISA. Cytokine content of cell-free supernatants was determined using commercial ELISA kits according to the manufacturer ' s instructions (IFN-␥ , Invitrogen; granzyme-B, Sanquin [provided by P de Koning, University Medical Center Utrecht, Utrecht, Netherlands]; IL-12-p70, eBioscience). The SEM of triplicate measurements never exceeded 10%.
Two-point pairwise linkage analysis. The mHag phenotypes of the CEPH individuals and 533 markers genotyped on CEPH families 1331, 1362, and 1408 were used as input to perform a genome-wide two-point linkage analysis using the subroutine MLINK of the FASTLINK program as previously described ( 8, 9, 17, 30, 31 ) .
Recombinant haplotype analysis. Genotype data for chromosome 16 were extracted from the CEPH database (version 10; http://www.cephb.fr/ cephdb/) to determine recombinant haplotypes in the CEPH families ( 32, 33 ( 34 ) , was used to analyze the correlation between the mHag zygosities and individual HapMap SNPs. For genome-wide analyses, ssSNPer was slightly modifi ed. We have shared this modifi ed ssSNPer at http:// www.umcutrecht.nl/subsite/dcch/Research/Hemato-Oncology/Identification-of-novel-GvT-associated-minor-H-antigens.htm. mHag zygosities (+/+, +/ Ϫ , and Ϫ / Ϫ ) of CEPH individuals were deduced from the Mendelian segregation pattern of the mHag phenotypes in their pedigrees. The
